In Alzheimer disease (AD) research and care, novel biomarkers that measure amyloid-β (Aβ) and phosphorylated tau (P-tau)–the principal components of amyloid plaques and neurofibrillary tangles–have facilitated early detection and biomarker-supported diagnosis.1 Therapeutics that modify the biology...
I guess for clinical use it doesn’t really matter? As long as there’s an effect on clinical endpoints.
You’re right, I just don’t like it when we invest huge sums on research based purely on clinical results. Better than models that don’t show efficacy in clinical trials, but still, magic drugs always bother me.
Yeah I get it. The companies developing these drugs or funding the research probably don’t care about fundamental knowledge. Even in pure academia people would probably rather have some publishable results than actual insight in a disease.
If they did, there could’ve been some psychiatric diseases that were actually understood as well.
Yeah, also read the abstract, it’s positive, but there are definite questions, the increase in ventricular volume was odd for one.
I just think we haven’t quite nailed the cause down yet, even if we’re close, there’s a wrinkle and trying to treat things we “almost understand” is risky (you can ‘cure’ some forms of mental illness with a lobotomy, but that’s not the point).